Provided by Tiger Trade Technology Pte. Ltd.

ABVC BioPharma, Inc.

1.51
-0.0200-1.31%
Post-market: 1.510.00000.00%16:10 EST
Volume:35.65K
Turnover:54.06K
Market Cap:36.69M
PE:-7.23
High:1.55
Open:1.52
Low:1.48
Close:1.53
52wk High:5.48
52wk Low:0.5900
Shares:24.30M
Float Shares:21.54M
Volume Ratio:0.94
T/O Rate:0.17%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2089
EPS(LYR):-0.4200
ROE:-47.71%
ROA:-17.22%
PB:3.04
PE(LYR):-3.60

Loading ...

Cingulate Inc.’s Promising Market Position Bolstered by Strategic Partnerships and Innovative ADHD Treatment

TIPRANKS
·
Nov 16, 2025

Press Release: Cybin Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights

Dow Jones
·
Nov 13, 2025

BrainsWay Receives FDA Clearance of Deep TMS™ as Adjunct Therapy for Major Depressive Disorder (MDD) in Adolescents Aged 15 to 21

GlobeNewswire
·
Nov 13, 2025

TRICARE West Expands NeuroStar® TMS Coverage to Include Adolescents Aged 15+ Struggling with Depression

GlobeNewswire
·
Nov 12, 2025

Press Release: Cingulate Names Industry Veteran Bryan Downey Chief Commercial Officer to Lead Launch Preparation for CTx-1301

Dow Jones
·
Nov 10, 2025

Mind Medicine price target raised to $25 from $16 at Canaccord

TIPRANKS
·
Nov 07, 2025

Press Release: MindMed Reports Q3 2025 Financial Results and Business Updates

Dow Jones
·
Nov 07, 2025

Yukiguni Maitake Sees FY Net Y2.01B

Dow Jones
·
Nov 06, 2025

ABVC BioPharma Q3 EPS $(0.05) Down From $(0.03) YoY, Sales $795.950K Up From $389.276K YoY

Benzinga
·
Nov 03, 2025

ABVC BioPharma Acquires Taiwan Land for $11 Million

Reuters
·
Nov 03, 2025

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Nov 01, 2025

ABVC Biopharma Ties Executive Compensation to $1B Market Cap Milestone

Reuters
·
Oct 30, 2025

Neuronetics Announces Three-Year Exclusive Partnership with Elite DNA Behavioral Health to Expand NeuroStar Access and Operational Excellence

GlobeNewswire
·
Oct 30, 2025

Supernus Pharmaceuticals Advances ADHD Treatment Study in Young Children

TIPRANKS
·
Oct 28, 2025

AbbVie’s Fosigotifator Study Termination: Impact on MDD Treatment Pipeline

TIPRANKS
·
Oct 28, 2025

Cingulate’s Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting

GlobeNewswire
·
Oct 24, 2025

Collegium Announces Poster Presentations at the American Academy of Child & Adolescent Psychiatry and Neuroscience Education Institute Conferences

GlobeNewswire
·
Oct 22, 2025

FDA Accepts Cingulate’s New Drug Application for CTx-1301 in Attention-Deficit/Hyperactivity Disorder (ADHD) and sets a May 31, 2026 PDUFA Date

GlobeNewswire
·
Oct 14, 2025

Collegium to Celebrate 10-Year Anniversary with Nasdaq Opening Bell Ringing

GlobeNewswire
·
Oct 13, 2025

Thomas Brown, Who Busted Myths Related to ADHD, Dies at 83 -- Journal Report

Dow Jones
·
Oct 10, 2025